

**February 12, 2019**

To,  
Department of Corporate Services  
**BSE Limited**  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001  
Scrip Code: **BSE - 524500**

To,  
Corporate Listing Department  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE - KILITCH**

Dear Sirs,

**Sub: Press Release**

We are pleased to enclosed herewith our Press Release relating to Financial Results for quarter & nine months ended 31<sup>st</sup> December 2018.

This is for your information and record.

Thanking you,

Yours Faithfully,  
For **Kilitch Drugs (India) Limited**

  
**Mukund Mehta**  
**Managing Director**  
**DIN:00147876**



**Encl: as above**





## **Kilitch Drugs (India) records 100% growth in Q3FY19**

*Net Sales up (YoY) by Rs. **6.50** crore  
Registers a net profit of Rs. 3.45 crore  
EPS for the third quarter stood at Rs. **2.14***

**BSE Code: 524500 NSE Code: KILITCH**

---

**FY18 Sales: Rs. 74.02 crore FY18 EBIDTA: Rs. 16.85 crore**

---

**Headquartered in Mumbai (India), with footprints in Indian, African and European markets**

---

**Product profile comprises injectables and OTC brands across parenteral & nasal products, oral, effervescent, nutritional products, medical devices and cosmetic and herbal products**

---

**Exhaustive experience in fast growing West African markets with more than 275 products registered and another 250 under registration**

---

**Mumbai – February 12, 2019:** The Board of Directors of Kilitch Drugs India Limited announced its un-audited results for the third quarter ended on December 31, 2018 following its approval by the Board of Directors in a meeting held in Mumbai on February 12, 2019.

### **Q3FY19 Performance (YoY)**

The company's total revenues increased to Rs. 19.65 crores as compared to Rs. 13.10 crores in the last financial year.

The net sales for Q3 stood at Rs. 19.33 crores – accounting for more than 50% of the company's net sales in FY18.

The company registered an EBIDTA (Earnings before Interest, Depreciation, Taxation & Amortization) improved to Rs. 4.83 crore as compared to Rs. 2.22 crore in Q3FY18.

The EBIDTA for the quarter accounted for Rs. 4.83 crore of the total EBIDTA posted in FY19 EBIDTA margin were driven by improved demand as well as professional efficiency and commitment.

Net profit for the quarter increased to Rs. 3.45 crores in Q3FY19 from Rs. 1.79 crores in Q3FY18.

Kilitch Drugs EPS has increased to Rs. 2.14 in December 2018 from Rs. 1.36 in December 2017.

**Speaking on the performance, Mr. Mukund P Mehta, Managing Director, Kilitch Drugs (India) Ltd.** stated, we have recorded robust growth during Q3 FY19 and look forward to maintaining our growth trajectory with a focus on strong asset quality, improved margins and enhanced market expansion across Africa. We hope to continue the ongoing momentum in the Q4 as well so we may end the financial year 2018-19 on a strong note.

#### **About Kilitch Drugs (India) Limited**

Kilitch Drugs was incorporated in May 1992 as a public limited company. The company went public in February 1994 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of injectables. The company believes Africa is the pharma market for next decade & working towards that goal by registering as many products possible to have a proper inroad in various east & west African countries.

For Information please contact [info@kilitch.com](mailto:info@kilitch.com) or visit [www.kilitch.com](http://www.kilitch.com)